Publications

Mongan NP, Martin KM, Gudas LJ.  2006.  The putative human stem cell marker, Rex-1 (Zfp42): structural classification and expression in normal human epithelial and carcinoma cell cultures.. Mol Carcinog. 45(12):887-900.

Mongan NP, Martin KM, Gudas LJ.  2006.  The putative human stem cell marker, Rex-1 (Zfp42): structural classification and expression in normal human epithelial and carcinoma cell cultures.. Mol Carcinog. 45(12):887-900.

Laursen KB, Mongan NP, Zhuang Y, Ng MM, Benoit YD, Gudas LJ.  2013.  Polycomb recruitment attenuates retinoic acid-induced transcription of the bivalent NR2F1 gene.. Nucleic Acids Res. 41(13):6430-43.

Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM.  2002.  Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.. Cancer. 95(6):1220-7.

David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM.  2010.  Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.. Cancer Biol Ther. 9(9):678-84.

Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MVallee, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ et al..  2007.  Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.. J Immunother. 30(6):655-62.

Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MVallee, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ et al..  2007.  Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.. J Immunother. 30(6):655-62.

Kubala JM, Laursen KB, Schreiner R, Williams RM, van der Mijn JC, Crowley MJ, Mongan NP, Nanus DM, Heller DA, Gudas LJ.  2023.  NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.. Cancer Biol Ther. 24(1):2170669.

Molina AM, van der Mijn JC, Christos P, Wright J, Thomas C, Dutcher JP, Nanus DM, Tagawa ST, Gudas LJ.  2020.  NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.. Invest New Drugs.

Marta M, Zhang T, Scognamiglio T, Gudas LJ.  2020.  Mutations in long-lived epithelial stem cells and their clonal progeny in pre-malignant lesions and in oral squamous cell carcinoma.. Carcinogenesis.

Mohn D, Chen SW, Dias DCampos, Weinstein DC, Dyer MA, Sahr K, Ducker CE, Zahradka E, Keller G, Zaret KS et al..  2003.  Mouse Mix gene is activated early during differentiation of ES and F9 stem cells and induces endoderm in frog embryos.. Dev Dyn. 226(3):446-59.

Nilsson EM, Laursen KB, Whitchurch J, McWilliam A, Ødum N, Persson JL, Heery DM, Gudas LJ, Mongan NP.  2015.  MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.. Oncotarget. 6(34):35710-25.

Nilsson EM, Laursen KB, Whitchurch J, McWilliam A, Ødum N, Persson JL, Heery DM, Gudas LJ, Mongan NP.  2015.  MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.. Oncotarget. 6(34):35710-25.

Williams RM, Shah J, Ng BD, Minton DR, Gudas LJ, Park CY, Heller DA.  2015.  Mesoscale nanoparticles selectively target the renal proximal tubule epithelium.. Nano Lett. 15(4):2358-64.

Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JLiao, Gudas LJ, Mongan NP.  2013.  The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.. Mol Oncol. 7(3):555-66.

Orfali N, Jeyapalan JN, Woodcock CL, O'Donovan TR, Benjamin D, Cahill M, McKenna S, Gudas LJ, Mongan NP.  2019.  Lentiviral-Mediated shRNA Approaches: Applications in Cellular Differentiation and Autophagy.. Methods Mol Biol. 2019:33-49.

Orfali N, Jeyapalan JN, Woodcock CL, O'Donovan TR, Benjamin D, Cahill M, McKenna S, Gudas LJ, Mongan NP.  2019.  Lentiviral-Mediated shRNA Approaches: Applications in Cellular Differentiation and Autophagy.. Methods Mol Biol. 2019:33-49.

Williams RM, Shah J, Mercer E, Tian HS, Thompson V, Cheung JM, Dorso M, Kubala JM, Gudas LJ, de Stanchina E et al..  2021.  Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury.. Front Pharmacol. 12:790913.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.

Orfali N, Shan-Krauer D, O'Donovan TR, Mongan NP, Gudas LJ, Cahill MR, Tschan MP, McKenna SL.  2019.  Inhibition of UBE2L6 attenuates ISGylation and impedes ATRA-induced differentiation of leukemic cells.. Mol Oncol.

Orfali N, Shan-Krauer D, O'Donovan TR, Mongan NP, Gudas LJ, Cahill MR, Tschan MP, McKenna SL.  2019.  Inhibition of UBE2L6 attenuates ISGylation and impedes ATRA-induced differentiation of leukemic cells.. Mol Oncol.

Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, Mongan NP, Gudas LJ, McKenna SL.  2015.  Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.. Exp Hematol. 43(9):781-93.e2.

Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, Mongan NP, Gudas LJ, McKenna SL.  2015.  Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.. Exp Hematol. 43(9):781-93.e2.